Marbofloxacin

Form: Tablet · Pack size: PK 100

Cats, Dogs

People with known hypersensitivity to (fluoro)quinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wash hands after use.

• Legal category: POM-V
• Marketing authorisation holder: KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia Further information Pharmacotherapeutic group: Antibacterials for systemic use, Fluoroquinolones. ATCvet code: QJ01MA93 Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase and of topoisomerase IV. It is effective against a wide range of Gram positive bacteria (including Streptococci and in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Citrobacter freundii, Proteus spp., Klebsiella spp, Shigella spp., Pasteurella spp., Pseudomonas spp.) as well as Mycoplasma spp. A secondary literature report of microbiological susceptibility data whose source included two European field surveys, each involving hundreds of canine and feline pathogens susceptible to marbofloxacin, was published in 2014. Microorganism MIC (µg/ml) Staphylococcus intermedius 0.250 Escherichia coli 0.030 Pasteurella multocida 0.030 Pseudomonas aeruginosa 0.500 Susceptibility break points have been determined as ≤1 µg/ml for sensitive, 2 µg/ml for intermediate and ≥4 µg/ml for resistant bacterial strains. Marbofloxacin is not active against anaerobes, yeast or fungi. Cases of resistance have been observed in Streptococcus. Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of efflux pump or mutation of enzymes responsible for molecule binding. In some Gram-negative bacteria, plasmid-mediated quinolone resistance has been reported. After oral administration in dogs and cats at the recommended dose of 2 mg/kg body weight, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 µg/ml within 2 hours. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly (t½ß = 14 h in dogs and 10h in cats) predominantly in the active form in urine (2/3) and faeces (1/3). Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products Medicines should not be disposed of via wastewater. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
• MA number: Quiflor 5mg Tablets for Cats and Dogs Vm 01656/4044 Quiflor 20mg Tablets for Dog Vm 01656/4045 Quiflor 80mg Tablets for Dogs Vm 01656/4046

The information on this page is provided for general guidance only and does not replace the advice of a qualified veterinary surgeon. Always follow the directions provided on the product packaging and by your veterinary practice. If your animal's condition does not improve, worsens, or any side effects occur, contact your veterinary surgeon immediately.